Barrack, Rodos & Bacine Investigates Napco Security Technologies, Inc. (NSSC)
August 24, 2023 09:30 ET | Barrack Rodos & Bacine
PHILADELPHIA, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Barrack, Rodos & Bacine (BR&B) is investigating Napco Security Technologies, Inc. (“Napco”) (NASDAQ: NSSC) for potential violations of federal...
Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
August 01, 2023 07:05 ET | uniQure Inc.
~ Announced encouraging interim analysis data from ongoing Phase I/II clinical trial of AMT-130 in Huntington’s disease showing preservation of function compared to baseline and clinical benefits...
Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 16, 2023 07:05 ET | uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, June 16, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces Sale of Royalty Interest in HEMGENIX® for Up To $400 Million
May 15, 2023 07:05 ET | uniQure Inc.
~ uniQure to receive $375 million upfront cash payment ~ ~ Under the existing agreement with CSL Behring, uniQure retains the rights to future milestones totaling up to $1.5 billion and maintains an...
Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
May 09, 2023 07:05 ET | uniQure Inc.
~ Clinical update from U.S. Phase I/II trial in Huntington’s disease expected in second quarter 2023 ~ ~ Continued progress towards initiating two new Phase I/II clinical studies for AMT-260 in...
Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2023 07:05 ET | uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, May 02, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
July 30, 2021 - ROSEN LOGO.jpg
EQUITY ALERT: ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Edgio, Inc. f/k/a Limelight Networks, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – EGIO, LLNW
April 27, 2023 12:23 ET | The Rosen Law Firm PA
NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Edgio,...
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
April 04, 2023 17:15 ET | The Rosen Law Firm PA
NEW YORK, April 04, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Phathom...
Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 13, 2023 07:05 ET | uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 13, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
Logo-uniQure-MS-Word_Orange.jpg
uniQure to Participate in Multiple Upcoming Industry Conferences in March
March 02, 2023 07:05 ET | uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 02, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...